RAPH vs MSFT: Which is Better to Buy in 2026?

Side-by-side fundamental comparison based on AI analysis of SEC filings

AI Verdict

MSFT has stronger fundamentals based on our AI analysis.

RAPH
Raphael Pharmaceutical Inc.
STRONG SELL
90%
Confidence
VS
MSFT
MICROSOFT CORP
BUY
91%
Confidence

RAPH vs MSFT Fundamental Comparison

Metric RAPH MSFT
Revenue N/A $158.9B
Net Income $-1.3M $66.2B
Net Margin N/A 41.7%
ROE N/A 16.9%
ROA -2,413.2% 10.0%
Current Ratio 0.03x 1.39x
Debt/Equity N/A 0.10x
EPS $0.07 $8.87

Green = Better metric | Red = Weaker metric

View Full RAPH Analysis →
View Full MSFT Analysis →
Browse Sectors: Technology Healthcare Finance Energy Consumer Industrial
Stock Lists: Strong Buy Undervalued Growth Dividend

You Might Also Compare

RAPH vs AAPL MSFT vs GOOGL RAPH vs AMZN MSFT vs NVDA

RAPH vs MSFT: Frequently Asked Questions

Is RAPH or MSFT a better buy in 2026?

Based on dual AI fundamental analysis (Claude and ChatGPT), MSFT has stronger fundamentals. RAPH is rated STRONG SELL (90% confidence) while MSFT is rated BUY (91% confidence). This is not investment advice.

How does RAPH compare to MSFT fundamentally?

Raphael Pharmaceutical Inc. has ROE of N/A vs MICROSOFT CORP's 16.9%. Net margins are N/A vs 41.7% respectively.

Which stock pays higher dividends, RAPH or MSFT?

RAPH has a dividend yield of N/A or no dividend while MSFT has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.

Should I invest in RAPH or MSFT for long term?

For long-term investing, consider that RAPH has STRONG SELL rating with 90% confidence, while MSFT has BUY rating with 91% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.

What do the AI models say about RAPH vs MSFT?

Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RAPH vs MSFT, the AI consensus favors MSFT based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.